Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
← catalyst calendarNCT06915025 · readout in 2,264 d
Sponsored by Imunon (industry) · IMNN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-09 | actual | When the study began enrolling |
| Primary completion | 2032-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epithelial Ovarian Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
- Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) — also filed as GEN-1
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Olaparib — also filed as Lynparza
- Drug: Niraparib — also filed as Zejula
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured 48 months
Permalink · IMNN's whole pipeline · Catalyst calendar · Every registered study · What changed